FDA ADE reports for Velagliflozin Proline Monohydrate (SGLT2 inhibitor (feline diabetes mellitus)) — total reports, species & reaction breakdown

ade_velagliflozin_proline_monohydrate_adverse_events

ade en 2026-07-22

Velagliflozin Proline Monohydrate — FDA Animal & Veterinary Adverse Event (ADE) Reports

Source: openFDA animalandveterinary/event.json, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Velagliflozin Proline Monohydrate is a SGLT2 inhibitor (feline diabetes mellitus).

Total reports

Velagliflozin Proline Monohydrate: 4357

Reports by species (top entries)

Cat 4051
Dog 72
Human 7
Horse 6
Lynx 2

Top reported reactions (VEDDRA terms, top entries)

Ketosis 1472
Lack of efficacy - NOS 1004
Weight loss 954
Diarrhoea 672
Vomiting 595
Lethargy (see also Central nervous system depression in Neurological) 522
Ketonuria 504
Anorexia 373
Death by euthanasia 242
Elevated blood urea nitrogen (BUN) 229

"Lack of efficacy" terms denote product-performance reports, not adverse reactions.

Source JSON: pdf-raw/ade/ade_active_ingredients_2026-07-22_b8.json (openFDA animalandveterinary/event.json, pulled 2026-07-22).

Sources

openFDA animalandveterinary/event.json (FDA CVM ADE), pulled 2026-07-22

Machine access

AI agents: this page mirrors GET /api/v1/llm_context?topic=ade_velagliflozin_proline_monohydrate_adverse_events (max 500 tokens, whitelisted). Rate limit 60 req/min for recognized AI crawlers.

Raw JSON ↗ llm.txt OpenAPI